Givosiran
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Givosiran: From Acute Hepatic Porphyria to ALA Dehydratase Deficiency Porphyria (ADP)
One-Sentence Summary
Givosiran is an siRNA therapeutic used for acute hepatic porphyria (AHP), a group of inherited heme biosynthesis disorders. Among the TxGNN model's predictions, only ALA dehydratase deficiency porphyria (ADP) — a rare AHP subtype — shows a genuine mechanistic link and supporting clinical/literature evidence; the other nine top-ranked predictions (hepatoportal sclerosis, portal vein thrombosis, hepatopulmonary syndrome, HBV/HCV infection, etc.) are flagged in the evidence pack itself as model artifacts sharing only a "liver" graph node, with no mechanistic basis and zero supporting studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute hepatic porphyria (AHP) — inferred from literature; no formal regulatory indication text available |
| Predicted New Indication | Porphyria due to ALA dehydratase deficiency (ADP) |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L2 |
| Norway Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data from a formal source is not available. Based on the literature evidence collected, givosiran is an siRNA therapeutic that silences hepatic ALAS1 (5-aminolevulinic acid synthase 1) mRNA, reducing hepatic overproduction of the neurotoxic intermediates ALA and PBG. This mechanism is the basis for its approval in acute hepatic porphyria (AHP), a family of four genetic disorders — including acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and ALA dehydratase deficiency porphyria (ADP) — that share the same downstream pathology of ALAS1-driven ALA/PBG accumulation.
ADP is therefore not really a "new" indication in the biological sense, but an ultra-rare subtype within the AHP family that givosiran's mechanism directly targets. This explains why this candidate — unlike the model's top-ranked outputs — carries genuine mechanistic and clinical support (L2, Phase 3 ENVISION data, an ADP-specific case report).
Important caveat on ranking: the nine other TxGNN predictions in this evidence pack (ranks 1–8 and 10, including hepatoportal sclerosis, portal vein thrombosis, hepatopulmonary syndrome, HBV/HCV infection, phenylalanine metabolism disorder, etc.) were explicitly annotated in the source data as having no mechanistic link and zero clinical trial or literature evidence — they appear to score highly only because they share a "liver" node with givosiran in the knowledge graph. All were scored L5/S0/Hold. This report therefore focuses on the one prediction (ADP, rank 9) that passed a minimal plausibility screen; the higher-ranked predictions should not be pursued without independent mechanistic justification.
Clinical Trial Evidence
Currently no related clinical trials registered (the ENVISION Phase 3 trial for AHP broadly is referenced only via post-hoc literature analysis, not as a registered trial record in this evidence pack).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36028858 | 2022 | RCT (Phase 3, ENVISION) | Orphanet J Rare Dis | Post-hoc analysis of the placebo-controlled ENVISION trial evaluating disease burden in AHP patients ≥12 years treated with givosiran |
| 40312531 | 2025 | Cohort/Clinical Study | Scientific Reports | Expanded access study in 10 Japanese AHP patients receiving monthly SC givosiran 2.5 mg/kg; efficacy and safety data |
| 35067977 | 2022 | Cohort (real-world) | J Intern Med | RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria |
| 37027823 | 2023 | Review | Blood | Overview of RNA interference therapy mechanism (ALAS1 silencing) across the acute hepatic porphyrias |
| 39313028 | 2024 | Review | Revista Clinica Espanola | Therapeutic approach to acute crises of hepatic porphyrias, including ALA dehydratase deficiency subtype |
| 35734365 | 2022 | Review | Drug Des Devel Ther | Design, development, and therapeutic placement of givosiran in adult AHP |
| 36883675 | 2023 | PK-PD Modeling | CPT: Pharmacometrics & Systems Pharmacology | PK-PD model of urinary ALA reduction after givosiran treatment, pooled Phase I-III data |
| 35991568 | 2022 | Case Report (non-response) | Frontiers in Genetics | Reports lack of response to givosiran in a confirmed ALAD porphyria (ADP) case — an important safety/efficacy caution signal |
Norway Market Information
Givosiran is currently not marketed in Norway (0 authorizations on file). No product, dosage form, or approved-indication data is available for this market.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not currently available in the evidence pack — this is flagged as a Blocking data gap (DG001) that must be resolved before any safety review can proceed.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Givosiran's core mechanism (hepatic ALAS1 silencing) is directly relevant to ADP, and this link is supported by Phase 3 ENVISION disease-burden data plus multiple reviews of the ALAS1/ALA-PBG pathway. However, ADP is an ultra-rare AHP subtype with essentially no ADP-specific trial data, and the one published ADP case report shows no clinical response to givosiran — so the mechanistic rationale does not guarantee efficacy in this subgroup, and guardrails (e.g., trial-basis use with close monitoring) are warranted rather than a full "Go."
Separately, the nine other TxGNN-predicted indications in this evidence pack lack any mechanistic or evidentiary support and should be held (Hold) pending independent validation — they are not addressed further in this report.
To proceed, the following is needed:
- TFDA/regulatory-source label data (key warnings, contraindications, DDI) — currently blocking (DG001)
- Formal MOA documentation from DrugBank or equivalent primary source (DG002)
- ADP subgroup-specific efficacy/safety data beyond the single non-responder case report
- Norway market entry status and regulatory pathway assessment, since the drug is not currently marketed there
- A structured safety monitoring plan should off-label or expanded-access use in ADP be considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.